SRTA Company Profile and Key Details

Strata Critical Medical, Inc. has 86.53 million shares outstanding. The public float is 57.36 million shares, elevated short interest at 6.38% of float. This equals 4.33 million shares. The short ratio is 3.22 days. Institutional investors hold 83.68% of the float. Insiders own 14.22%. Tomkiel Melissa M. holds 1.89 million shares, Heyburn William A. has 1.55 million shares and Wunsch Scott M has 625.57 thousand shares. Over the past six months, insider transactions show net selling. They sold 141.88 thousand shares across 8 transactions.

Short-term trend indicators are mixed aligned (SMA20 -3.05%, SMA50 -11.97%, SMA200 -2.57%). The stock’s 14-day RSI is 42.94 (neutral), while the ATR of 0.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -26.41% below its high and over 88.5% above its low. Average 10-day trading volume of 824.84 thousand shares is below the 3-month average of 1.12 million, indicating normal recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Strata Critical Medical, Inc. (NASDAQ:SRTA) closed at $5.20 USD, gaining $0.07 (1.27%) from the previous close of $5.13. The stock is currently mid-range between its 52-week high and low $3.95 and $6.50. With a market capitalization of about $449.51 million, Strata Critical Medical, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.26). Key stats such as the average daily volume over the past year has been around 1.12 million shares, volume is running light vs its 52-week average. Headquartered in New York, NY, Strata Critical Medical, Inc. operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Melissa Tomkiel, the company employs approximately 327 people and listed since November 05, 2019. Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $7.25. The high target offers 53.85% upside. The low target suggests 39.42% downside. The mean target is $7.81. This offers 50.19% upside. Strata Critical Medical, Inc. earnings surprise history is a mixed track record. The quarter that ended August 04, 2026, missed forecasts by 500.0%. The prior quarter beat by -175.0%. Over the last six quarters, Apple has recorded several small beats. These include -63.64% in May 12, 2025.

Strata Critical Medical, Inc. trades at a P/E ratio of 10.37, slightly below the S&P 500 average, with a price-to-sales ratio of 1.75 and a price-to-book ratio of 1.6 suggesting the stock is closer to book value. The P/FCF stands at -10.26, also below market averages.

Strata Critical Medical, Inc. (NASDAQ:SRTA) shares are up 19.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Strata Critical Medical, Inc. trading at a premium to the broader market with a P/E of 10.37. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.81, suggesting 50.19% upside. Our AI forecast model points to short-term weakness (-15.0% over two weeks), a medium-term rise (7.88% over three months), and a longer-term gain (308.08% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Strata Critical Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.0%, with price expected at $4.42 by September 25, 2026, within a range of $4.18 to $4.66 3-Month Outlook: Projected rise of 7.88%, reaching $5.61 by December 10, 2026, with a range of $5.52 to $5.69. 1-Year Outlook: Projected gain of 308.08%, with price at $21.22 by September 10, 2027, within a range of $21.16 to $21.30.